Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emapalumab + ruxolitinib
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Emapalumab + ruxolitinib is a combination therapy being investigated for the treatment of hemophagocytic lymphohistiocytosis (HLH). Emapalumab is a fully human IgG1 monoclonal antibody that binds to and neutralizes interferon-gamma (IFN-γ), a key driver of HLH pathogenesis. Ruxolitinib is a small molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), which mediates signaling downstream of various pro-inflammatory cytokines, including IFN-γ. By combining these two agents, the regimen aims to provide a dual-pronged approach: emapalumab directly blocks the IFN-γ protein, while ruxolitinib inhibits the signaling pathways activated by residual IFN-γ and other cytokines involved in the "cytokine storm" characteristic of HLH. This specific dose-modified regimen is being evaluated in Phase III clinical trials led by The First Affiliated Hospital of Soochow University to improve efficacy and safety in patients with active, relapsed, or refractory HLH.
- Other names
- dose-modified Emapalumab and RuxolitinibEmapalumab and Ruxolitinib combination
02
Targets
Beyond the preview
Go deeper on emapalumab + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emapalumab + ruxolitinib.